Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension

Inclusion Criteria: 1. Male and female patient aged 19 and older 2. In patient diagnosed with essential hypertension, * Patients who can be first treated with NEBILET®(Nebivolol) to lower high blood pressure * In patients who are receiving other antihypertensive medications, those who can switch one of the antihypertensive agents to NEBILET®(Nebivolol) or use NEBILET®(Nebivolol) as an additional therapy (In case where one of other antihypertensive agents is switched to NEBILET®(Nebivolol), it is imperative that the dose of the previous medication should exhibit the same antihypertensive effect as NEBILET®(Nebivolol) 5 mg.) 3. Subjects who have signed the written informed consent form for their voluntary participation Exclusion Criteria: 1. Patient with hypersensitivity to the NEBILET®(Nebivolol) substance 2. Patient with history of bronchospasm 3. Patient with history of bronchial asthma 4. Patient with metabolic acidosis 5. Patient with bradycardia(heart rate\< 60 bpm) 6. Patient with second and third degree atrioventricular block 7. Patient with acute heart failure, cardiogenic shock, or episodes of heart failure decompensation requiring i.v. inotropic therapy) 8. Patient with uncontrolled severe heart failure 9. Patient with hypotension (Systolic Blood Pressure \< 90mmHg) 10. Patient with severe peripheral circulatory disturbances 11. Patient with sick sinus syndrome including sino-atrial block 12. Patient with untreated pheochromocytoma 13. Patient with hepatic insufficiency 14. Patient with impaired liver function 15. Pregnant woman 16. Nursing mother 17. Patient with chronic heart failure who has severe renal insufficiency (serum creatinine ≥ 250 micro mol/L) 18. Patient with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption 19. Patient who has participated in other clinical trial within the last 3 months